Monoclonal antibodies to the CD25 (IL-2a) receptors are used for a treatment of:
High-Yield Explanation
(Antibodies to CD 25) -Basiliximab reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of oppounistic infections.